Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | RAD52 | P43351 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154457 | 0.86 | KDM1A (0.59) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL17423211 | 0.83 | KDM1A (0.75) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4907330 | 0.83 | EGFR (0.49) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4933340 | 0.82 | KDM1A (0.57) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4911311 | 0.81 | KDM1A (0.51) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4904565 | 0.81 | TOP2A (0.59) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4912830 | 0.80 | KDM1A (0.49) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4910466 | 0.79 | KDM1A (0.49) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL17154429 | 0.78 | KDM1A (0.64) | KDM1APOLBRAD52KMT2AKDM4E | |
| SCHEMBL4904556 | 0.78 | IGF1R (0.48) | KDM1APOLBRAD52KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | MiRx Pharmaceuticals, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2015153535-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MiRx Pharmaceuticals, LLC (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | TP53, DDX3X, API5 | KDM1A 702/4885POLB 3707/4885RAD52 477/4885 |
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | TP53, MDM4, MDM2 | KDM1A 650/4885POLB 3690/4885RAD52 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.